Frequency of Obtaining National Cholesterol Education Program Adult Treatment Panel III Goals for All Major Serum Lipoproteins After Initiation of Lipid Altering Therapy

American Journal of Cardiology

Volumn 104, Issue 12, 2009, Pages 1689-1694

  Nichols, Gregory A ^a   Ambegaonkar, Baishali M ^b   Sazonov, Vasilisa ^b   Brown, Jonathan B ^a  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DYSLIPIDEMIA; EDUCATION PROGRAM; FEMALE; GOAL ATTAINMENT; HEALTH MAINTENANCE ORGANIZATION; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; TREATMENT OUTCOME;

EID: 70749137225     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.07.050     Document Type: Article

References (18)

1. Grant R.W., and Meigs J.B. Prevalence and treatment of low HDL Cholesterol among primary care patients with type 2 diabetes: An unmet challenge for cardiovascular risk reduction. Diabetes Care 30 (2007) 479-484
2. Nichols G.A., Nag S., and Chan W. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. Am Heart J 154 (2007) 554-560
3. Anderson K.M., Odell P.M., Wilson P.W.F., and Kannel W.B. Cardiovascular disease risk profiles. Am Heart J 121 (1990) 293-298
4. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
5. Grundy S.M., Cleeman J.I., Bairey-Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., Stone N.J., and Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
6. Ghandehari H., Kamal-Bahl S., and Wong N.D. Prevalence and extent of dyslipidemia and recommended lipid levels in US adult with and without cardiovascular comorbidities: The National Health and Nutrition Examination Survey 2003-2004. Am Heart J 156 (2008) 112-119
7. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., and Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
8. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention study. Circulation 102 (2000) 21-27
9. Hausenloy D.J., and Yellon D.M. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 94 (2008) 706-714
10. Kastelein J.J.P., van der Steeg W.A., Holme I., Gaffney M., Cater N.B., Barter P., Deedwania P., Olsson A.G., Boekholdt M., Demicco D.A., Szarek M., LaRosa J.C., Pedersen T.R., Grundy S.M., and TNT and IDEAL Study Groups. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117 (2008) 3002-3009
11. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., and Albers J.J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
12. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., Jure H., De Larochelliere R., Staniloae C.S., Mavromatis K., Saw J., Hu B., Lincoff A.M., Tuzcu E.M., and PERISCOPE Investigators. Comparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. JAMA 299 (2008) 1561-1573
13. Davidson M., Meyer P.M., Haffner S., Feinstein S., D'Agostino Sr. R., Kondos G.T., Perez A., Chen Z., and Mazzone T. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 117 (2008) 2123-2130
14. Pearson T.A., Laurora I., Chu H., and Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 (2000) 459-467
15. Yan A.T., Yan R.T., Tan M., Hackam D.G., Leblanc K.L., Kertland H., Tsang J.L., Jaffer S., Kates M.L., Leiter L.A., Fitchett D.H., Langer A., Goodman S.G., and Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 119 (2006) 676-683
16. Davidson M.H., Maki K.C., Pearson T.A., Pasternak R.C., Deedwania P.C., McKenney J.M., Fonarow G.C., Maron D.J., Ansell B.J., Clark L.T., and Ballantyne C.M. Results of the National Cholesterol Education Program (NCEP) Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96 (2005) 556-563
17. Massing M.W., Sueta C.A., Chowdhury M., Biggs D.P., and Simpson R.J. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol 87 (2001) 646-649
18. Afonso N.W., Nassif G., Aranha A.N.F., DeLor B., and Cardozo L.J. Low-density lipoprotein cholesterol goal attainment among high risk patients: does a combined intervention targeting patients and providers work?. Am J Manag Care 12 (2006) 589-594